Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The clinical trial comparing unfractionated and low-molecular-weight heparin for the treatment of VTE by Dr Kearon and colleagues1 lacks an important component recommended by the CONSORT statement: a justification for the chosen noninferiority margin.2 The authors' assertion of noninferiority of unfractionated heparin is called into question by this omission, combined with the enrollment of fewer patients than planned, as well as recent reports of a trend in favor of low-molecular-weight heparin compared with intravenous unfractionated heparin.3,4
Edwards JL. Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism. JAMA. 2007;297(3):261-263. doi:10.1001/jama.297.3.262-a